VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2017 | The Hokusai VTE-Cancer Study: the importance of improving VTE treatment

Venous thromboembolism (VTE) remains a major risk for patients with cancer. The current standard of care for VTE includes subcutaneously injecting low-molecular-weight heparin (LMWH), which has shown to be effective; however, patients are required to use this treatment for prolonged periods. In this interview, recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Harry Buller, MD, PhD, of the Academic Medical Centre, Amsterdam, Netherlands, discusses the issues surrounding VTE. Prof. Buller also explains the reasoning behind the Hokusai VTE-Cancer Study (NCT02073682), which compared subcutaneous injection of LMWH vs. oral edoxaban for the treatment of VTE.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter